title: Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrombosis.
abstract: Atherosclerosis is the most common pathological process underlying cardiovascular diseases. Current therapies are largely focused on alleviating hyperlipidaemia and preventing thrombotic complications, but do not completely eliminate risk of suffering recurrent acute ischaemic events. Specifically targeting the inflammatory processes may help to reduce this residual risk of major adverse cardiovascular events in atherosclerotic patients. The involvement of neutrophils in the pathophysiology of atherosclerosis is an emerging field, where evidence for their causal contribution during various stages of atherosclerosis is accumulating. Therefore, the identification of neutrophils as a potential therapeutic target may offer new therapeutic perspective to reduce the current atherosclerotic burden. This narrative review highlights the expanding role of neutrophils in atherogenesis and discusses on the potential treatment targeting neutrophil-related inflammation and associated atherosclerotic plaque vulnerability.
authors.forename: Ana Luíza
authors.initials: AL
authors.lastname: Gomes Quinderé
authors.forename: Norma Maria Barros
authors.initials: NM
authors.lastname: Benevides
authors.forename: Federico
authors.initials: F
authors.lastname: Carbone
authors.forename: François
authors.initials: F
authors.lastname: Mach
authors.forename: Nicolas
authors.initials: N
authors.lastname: Vuilleumier
authors.affiliation: Fabrizio Montecucco, MD, PhD, Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland, Tel: +41 22 38 27 238, Fax: +41 22 38 27 245, E mail: Fabrizio.montecucco@unige.ch.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Montecucco
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000276:immunology / Q000628:therapy*; D015815:Cell Adhesion Molecules / Q000276:immunology; D018925:Chemokines / Q000276:immunology; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D020556:Neutrophil Infiltration / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D019707:Receptors, Chemokine / Q000276:immunology; D013927:Thrombosis / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D018925:Chemokines; D019707:Receptors, Chemokine
keywords: Atherosclerosis; inflammation; neutrophil